As global markets navigate a period of heightened economic activity and mixed signals from earnings reports, investors are keenly observing the performance of major indices, which have seen fluctuations amid busy data weeks. With value stocks showing resilience compared to their growth counterparts, this environment presents an opportunity to identify stocks that may be trading below their intrinsic worth. In such a climate, finding undervalued stocks requires a focus on strong fundamentals and potential for recovery or growth despite broader market volatility.
Name | Current Price | Fair Value (Est) | Discount (Est) |
Provident Financial Services (NYSE:PFS) | US$18.85 | US$37.47 | 49.7% |
Proya CosmeticsLtd (SHSE:603605) | CN¥97.24 | CN¥194.47 | 50% |
Arteche Lantegi Elkartea (BME:ART) | €6.10 | €12.20 | 50% |
Elica (BIT:ELC) | €1.725 | €3.44 | 49.8% |
Beyout Investment Group Holding Company - K.S.C. (Holding) (KWSE:BEYOUT) | KWD0.395 | KWD0.79 | 50% |
Bangkok Genomics Innovation (SET:BKGI) | THB2.68 | THB5.35 | 49.9% |
BayCurrent Consulting (TSE:6532) | ¥4902.00 | ¥9762.93 | 49.8% |
Redcentric (AIM:RCN) | £1.20 | £2.39 | 49.8% |
Beijing LeiKe Defense Technology (SZSE:002413) | CN¥4.72 | CN¥9.39 | 49.8% |
Alnylam Pharmaceuticals (NasdaqGS:ALNY) | US$273.91 | US$546.14 | 49.8% |
Click here to see the full list of 955 stocks from our Undervalued Stocks Based On Cash Flows screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Overview: argenx SE is a biotechnology company focused on developing therapies for autoimmune diseases across the United States, Japan, Europe, the Middle East, Africa, and China with a market cap of €32.98 billion.
Operations: The company generates revenue from its biotechnology segment, amounting to $1.91 billion.
Estimated Discount To Fair Value: 44.8%
argenx is trading significantly below its estimated fair value, with a valuation gap exceeding 20% based on discounted cash flow analysis. Recent FDA approval of VYVGART Hytrulo for CIDP and strong clinical trial results bolster its growth prospects. Despite notable insider selling, revenue is forecast to grow at 26.2% annually, outpacing the Belgian market's average, and earnings are expected to increase by 58.04% per year as profitability approaches within three years.
Overview: GFL Environmental Inc. provides non-hazardous solid waste management and environmental services in Canada and the United States, with a market cap of CA$22.84 billion.
Operations: The company's revenue segments consist of CA$4.79 billion from U.S. solid waste, CA$2.16 billion from Canadian solid waste, and CA$1.67 billion from environmental services.
Estimated Discount To Fair Value: 28.5%
GFL Environmental is trading 28.5% below its estimated fair value of CA$81.21, based on discounted cash flow analysis. The company aims to enhance its capital structure by transitioning more debt from secured to unsecured through a US$210 million bond offering, which was significantly oversubscribed. Despite recent insider selling and past shareholder dilution, GFL's earnings are forecasted to grow substantially at 117.13% annually as it moves toward profitability within three years.
Overview: Dino Polska S.A. operates a network of mid-sized grocery supermarkets under the Dino brand in Poland, with a market capitalization of PLN32.52 billion.
Operations: The company's revenue is primarily generated from its network of mid-sized grocery supermarkets in Poland.
Estimated Discount To Fair Value: 30.6%
Dino Polska is trading at PLN 331.7, significantly below its estimated fair value of PLN 478.23, suggesting undervaluation based on cash flows. Despite a recent dip in quarterly net income to PLN 347.87 million from PLN 362.19 million, earnings have consistently grown over the past five years and are forecasted to grow faster than the Polish market at 17.4% annually, supported by robust revenue growth projections of 14.7% per year.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTBR:ARGX TSX:GFL and WSE:DNP.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。